

## HYPOGLYCEMICS, INCRETIN MIMETICS (GLP-1 receptor agonists) PRIOR AUTHORIZATION FORM

(form effective 01/05/2021)

Prior authorization guidelines for Hypoglycemics, Incretin Mimetics/Enhancers and Quantity Limits/Daily Dose Limits are available on Geisinger Health Plan's website at <https://healthplan.geisinger.org/pharmacy/pharmacy.aspx?strip=true&style=OneGeisinger>

<input type="checkbox"/> New request <input type="checkbox"/> Renewal request		Total # pages: _____	Prescriber name: _____	
Name of office contact: _____		Specialty: _____		
Phone number of office contact: _____		NPI: _____	State license #: _____	
Facility contact/phone: _____		Street address: _____		
Beneficiary name: _____		Suite #: _____	City/state/zip: _____	
Beneficiary ID#: _____	DOB: _____	Phone: _____	Fax: _____	

### CLINICAL INFORMATION

Refer to <https://papdl.com/preferred-drug-list> for a list of preferred and non-preferred drugs in each class

Drug requested: _____	Strength: _____
Dose/directions: _____	Quantity: _____    Refills: _____
Diagnosis ( <u>Submit documentation</u> ): _____	Dx code ( <u>required</u> ): _____
Does the beneficiary have a diagnosis of type 2 diabetes?	<input type="checkbox"/> Yes – <i>Submit documentation of diagnosis</i> <input type="checkbox"/> No – <i>Submit medical literature supporting the use of the requested medication for the beneficiary's diagnosis.</i>
<p><b><u>Requests for a NON-PREFERRED medication:</u></b> Please list the preferred Hypoglycemics, Incretin Mimetics (GLP-1 receptor agonists) that the beneficiary has had a therapeutic failure, contraindication, or intolerance to. Refer to <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred drugs in each class</p>	<p><i>Submit all supporting documentation of preferred agents tried and treatment outcomes, including contraindications or intolerances.</i></p>
Will the beneficiary be using the requested GLP-1 receptor agonist in addition to a DPP-4 inhibitor (e.g., Janumet, Januvia, Onglyza, Tradjenta, etc.) or Symlin or another GLP-1 receptor agonist ?	<input type="checkbox"/> Yes – <i>Submit medical literature supporting the concomitant use of these medications</i> <input type="checkbox"/> No
<p><b>Check all of the following that apply to the beneficiary and this request and SUBMIT DOCUMENTATION for each item.</b></p> <p><input type="checkbox"/> Has a history of trial and failure of maximum tolerated doses of metformin as evidenced by HbA1c results. Provide HbA1c value: _____</p> <p><input type="checkbox"/> Has a contraindication or intolerance to metformin</p> <p><input type="checkbox"/> Requires initial dual therapy with metformin based on HbA1c as defined by current ADA and/or AACE/ACE guidelines. Provide HbA1c value: _____</p> <p><input type="checkbox"/> Has the following comorbidities:</p> <p style="margin-left: 20px;"><input type="checkbox"/> cardiovascular disease</p> <p style="margin-left: 20px;"><input type="checkbox"/> at least 2 risk factors for cardiovascular disease. Please provide the member's risk factors for CVD: _____</p> <p style="margin-left: 20px;"><input type="checkbox"/> heart failure</p> <p style="margin-left: 20px;"><input type="checkbox"/> chronic kidney disease</p>	

**Please submit to PromptPA <https://ghp.promptpa.com> OR fax to Geisinger Health Plan at 570-271-5610 the completed form with required clinical documentation.**

Prescriber Signature: _____	Date: _____
-----------------------------	-------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.